Industry News & Announcements
Industry News & Announcements
On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being developed by NeuExcell Therapeutics Inc. ("NeuExcell"), for the treatment of malignant glioma. This is the world's first AAV gene therapy product for malignant glioma to receive FDA ODD designation.
NeuExcell Therapeutics inc.Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.